Ehave, Inc. Expands Its KetaDASH Brand And Begins Producing Revenue With The Purchase Of California Based Rejuv IV
Ehave, Inc. Expands Its KetaDASH Brand And Begins Producing Revenue With The Purchase Of California
February 9, 2022
Ehave, Inc. Expands Its KetaDASH Brand And Begins Producing Revenue With The Purchase Of California
Braxia Scientific Provides Update on Large Proprietary Dataset Expected to Support Pharmaceutical and Industry Clinical
PharmaTher Granted FDA Orphan Drug Designation for Ketamine to Treat Status Epilepticus PharmaTher (PHRM) is
Perception study may explain promising depression therapy Our brains are constantly making predictions about the
Pasithea Therapeutics Announces Opening of Mental Health Clinic in Los Angeles and Broadens Focus Beyond
How can DMT be improved to better treat addiction? How do our genetics influence our
Survey Finds Majority of Affected Americans Approve of Psychedelics as an Alternative Treatment to Address
January 2022 Corporate Update Delic Holdings Corp. (DELC) announced that it plans to more than
Novamind Hosts Pioneering Psychedelic Clinical Trial for Opioid Use Disorder Novamind (NM) is hosting a
atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program atai
PharmaTher Announces FDA Approval of Investigational New Drug (IND) Application for Ketamine to Treat ALS
After his brother overdosed in 2019, Timothy Ko founded Entheon Biomedical (ENBI) on his quest
Institutional Review Board Grants Approval for Cybin-Sponsored Feasibility Study Using Kernel Flow Technology to Measure
Awakn Life Sciences Expands World’s First Ketamine Study Beyond Gambling Disorder To Include Additional Behavioral
PharmaTher Announces Publication of Research Data for KETABET™ Second published study to demonstrate the potential
PharmaTher Provides Update on Product Pipeline and Expected Milestones for 2022 Focused on becoming a
Pasithea Therapeutics Opens Second Ketamine Therapy Clinic in the United Kingdom — Expanding Pasithea Clinics
PharmaTher Enters Into Process Development Agreement With LTS Lohmann for Ketamine Microneedle Patch TORONTO/ANDERNACH, December
Ketamine Wellness Centers Opening Salt Lake City & Reno Locations KWC Expands to Include 12
Pasithea Therapeutics Expands its Mobile Clinics into Florida and Nevada — Pasithea Clinics commences in-home
PharmaTher Granted New Japanese Patent for KETABET™ (Ketamine Combination Formulation), Strengthening Global Patent Portfolio PharmaTher
Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma’s Proprietary Wafer-Based Delivery Platform
PharmaTher Applies for FDA Orphan Drug Designation for Ketamine to Treat Rare Neurological Disorder Status
PharmaTher Applies for FDA Orphan Drug Designation for Ketamine to Treat Rare Neurological Disorder Status